Glycine-site NMDA receptor antagonists: An update

Expert Opinion on Therapeutic Patents

Volumn 6, Issue 10, 1996, Pages 1069-1079

  Kulagowski, J J ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 QUINOXALINEDIONE DERIVATIVE; 5,7 DICHLORO 1,2,3,4 TETRAHYDRO 4 (3 PHENYLUREIDO) 2 QUINOLINECARBOXYLIC ACID; 5,7 DICHLOROKYNURENIC ACID; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; 7 CHLORO 1,2,5,10 TETRAHYDRO 4 HYDROXY 2 (4 METHOXY 2 METHYLPHENYL)PYRIDAZINO[4,5 B]QUINOLINE 1,10 DIONE; 7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; 7 [[4 [BIS(4 FLUOROPHENYL)METHYL] 1 PIPERAZINYL]METHYL] 2 [(2 HYDROXYETHYL)AMINO] 4 ISOPROPYL 2,4,6 CYCLOHEPTATRIEN 1 ONE; ANTIOXIDANT; CALCIUM ANTAGONIST; DIZOCILPINE; ELIPRODIL; GAVESTINEL; GLUTAMIC ACID; GLYCINE; GLYCINE RECEPTOR; GLYCINE RECEPTOR ANTAGONIST; KAINIC ACID; KYNURENIC ACID DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; PYRIDONE DERIVATIVE; TENOCYCLIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL MODEL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DROWSINESS; DRUG RESEARCH; EPILEPSY; HEAD INJURY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEUROPROTECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PATENT; REVIEW; SCHIZOPHRENIA; STROKE; VERTIGO;

EID: 0029788672     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.6.10.1069     Document Type: Review

References (0)